Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - GOOD-IDES

NCT03157037 is registered in ClinicalTrials.gov with Mårten Segelmark as lead sponsor.

NCT NCT03157037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03157037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - GOOD-IDES
Lead sponsor
Mårten Segelmark
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2017
Completion date
July 24, 2020
Enrollment
15 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anti-glomerular basement membrane antibody disease